Hydroxychloroquine has been an FDA-approved medication since 1955. For 65 years before COVID-19, it was considered so safe that it was approved for use during pregnancy and was on the WHO's List of Essential Medicines. Lupus patients took it daily for years — sometimes decades — without serious adverse effects. Rheumatoid arthritis patients relied on it as a first-line treatment.
Then, in the spring of 2020, something extraordinary happened. A medication that had been used continuously for 65 years with a well-established safety profile became the center of one of the most intense medical and political controversies in recent memory.
What the Lupus Community Knew
When HCQ was being attacked as dangerous in 2020, lupus patients were some of its most vocal defenders — and for good reason. They had taken it every day for years. The Lupus Foundation of America noted that hydroxychloroquine was the single most important medication in lupus treatment. When supplies were disrupted by COVID-related demand, lupus patients were the ones who suffered.
These patients knew firsthand that the safety fears being amplified in 2020 bore no resemblance to clinical reality. The cardiac risks that were being cited — long QT syndrome — are real but extremely rare, well-characterized, and easily monitored with a baseline EKG. They were not new discoveries. They had been known and managed for decades.
The Zinc Synergy
One of the most important pieces of context missing from mainstream coverage of HCQ was the zinc synergy. Hydroxychloroquine is a zinc ionophore — it helps zinc ions cross the cell membrane into the cell interior. Zinc, once inside, inhibits the RNA-dependent RNA polymerase that RNA viruses like SARS-CoV-2 use to replicate. HCQ without zinc is far less effective. HCQ with zinc, administered early, was the protocol being advocated by frontline physicians — not the high-dose, late-stage administration used in the controversial hospital trials.
Early Treatment Was the Key
Every physician who argued for HCQ in 2020 — Drs. Harvey Risch, Zelenko, McCullough, and many others — specified early outpatient treatment. The studies that were used to discredit HCQ predominantly examined hospitalized patients who were already severely ill. Administering an early-treatment drug late in disease progression and then claiming it doesn't work is not good science. It's a manipulation of the research framework.
The Right to Choose
Ultimately, the HCQ controversy was not primarily about science. It was about control. The right of a patient and their physician to make a medical decision — using a 65-year-old, off-patent, inexpensive drug — was overridden by regulatory agencies, pharmacy chains, and media pressure. This is not how medicine in a free country is supposed to work.
Key Takeaway: Hydroxychloroquine's decades-long safety record in lupus and RA patients was never in serious doubt — and early treatment protocols that included zinc deserved the rigorous, unbiased clinical investigation they were denied.